| Target Price | $34.17 | 
| Price | $21.47 | 
| Potential | 
      
            
    
      
    
  59.15%
     register free of charge | 
| Number of Estimates | 21 | 
| 21 Analysts have issued a price target Apellis Pharmaceuticals, Inc. 2026 .
        The average Apellis Pharmaceuticals, Inc. target price is $34.17.
        This is 
       
    
      
    
  59.15%
     register free of charge 
                $63.00 
    
      
    
  193.43%
     register free of charge 
                $18.18 
    
      
    
  15.32%
     register free of charge | |
| A rating was issued by 27 analysts: 18 Analysts recommend Apellis Pharmaceuticals, Inc. to buy, 8 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Apellis Pharmaceuticals, Inc. stock has an average upside potential 2026 of 
       
    
      
    
  59.15%
     register free of charge | 
| Dec '24 | 2025 Estimates | |
|---|---|---|
| Revenue Million $ | 781.37 | 951.34 | 
| 97.02% | 21.75% | |
| EBITDA Margin | -20.88% | 11.53% | 
| 83.93% | 155.21% | |
| Net Margin | -25.32% | -7.03% | 
| 81.00% | 72.24% | 
22 Analysts have issued a sales forecast Apellis Pharmaceuticals, Inc. 2025 . The average Apellis Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
11 Analysts have issued an Apellis Pharmaceuticals, Inc. EBITDA forecast 2025. The average Apellis Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
22 Apellis Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Apellis Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 | 2025 Estimates | |
|---|---|---|
| Earnings Per Share $ | -1.60 | -0.53 | 
| 64.04% | 66.88% | |
| P/E | negative | |
| EV/Sales | 2.84 | 
22 Analysts have issued a Apellis Pharmaceuticals, Inc. forecast for earnings per share. The average Apellis Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Apellis Pharmaceuticals, Inc....
| Analyst | Rating | Action | Date | 
|---|---|---|---|
| Wells Fargo | Locked ➜ Locked | Locked | Oct 15 2025 | 
| Goldman Sachs | Locked ➜ Locked | Locked | Sep 26 2025 | 
| JP Morgan | Locked ➜ Locked | Locked | Aug 04 2025 | 
| Raymond James | Locked ➜ Locked | Locked | Aug 01 2025 | 
| RBC Capital | Locked ➜ Locked | Locked | Aug 01 2025 | 
| Cantor Fitzgerald | Locked ➜ Locked | Locked | Aug 01 2025 | 
| Citigroup | Locked ➜ Locked | Locked | Aug 01 2025 | 
| Analyst Rating | Date | 
|---|---|
| Locked 
            Wells Fargo:
             Locked ➜ Locked | Oct 15 2025 | 
| Locked 
            Goldman Sachs:
             Locked ➜ Locked | Sep 26 2025 | 
| Locked 
            JP Morgan:
             Locked ➜ Locked | Aug 04 2025 | 
| Locked 
            Raymond James:
             Locked ➜ Locked | Aug 01 2025 | 
| Locked 
            RBC Capital:
             Locked ➜ Locked | Aug 01 2025 | 
| Locked 
            Cantor Fitzgerald:
             Locked ➜ Locked | Aug 01 2025 | 
| Locked 
            Citigroup:
             Locked ➜ Locked | Aug 01 2025 | 
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


